EP0953038A1 - Novel process for the propagation of b. pertussis - Google Patents
Novel process for the propagation of b. pertussisInfo
- Publication number
- EP0953038A1 EP0953038A1 EP96938077A EP96938077A EP0953038A1 EP 0953038 A1 EP0953038 A1 EP 0953038A1 EP 96938077 A EP96938077 A EP 96938077A EP 96938077 A EP96938077 A EP 96938077A EP 0953038 A1 EP0953038 A1 EP 0953038A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pertussis
- medium
- fha
- range
- pva
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000008569 process Effects 0.000 title claims abstract description 13
- 241000588832 Bordetella pertussis Species 0.000 title claims description 41
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 26
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 26
- 229960005486 vaccine Drugs 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims description 25
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000007062 hydrolysis Effects 0.000 claims description 14
- 238000006460 hydrolysis reaction Methods 0.000 claims description 14
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 230000001502 supplementing effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 108010021711 pertactin Proteins 0.000 claims description 3
- 230000001902 propagating effect Effects 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 abstract description 16
- 239000000427 antigen Substances 0.000 abstract description 3
- 102000036639 antigens Human genes 0.000 abstract description 3
- 108091007433 antigens Proteins 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract description 3
- 241000588807 Bordetella Species 0.000 abstract description 2
- 230000001976 improved effect Effects 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 23
- 201000005702 Pertussis Diseases 0.000 description 10
- 239000006260 foam Substances 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000309219 Sium medium Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241000917014 Bordetella pertussis 18323 Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001510071 Pyrrhocoridae Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- -1 dimethyl cyclodextrin Chemical compound 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- This invention relates to a process for culturing bacteria belonging to the genus Bordetella for isolation of antigenic proteins useful in the production of whooping cough vaccine.
- the invention relates to a process for improving the yield of the major protein components FHA and PT which are secreted into the culture medium during bacterial growth of Bordetella pertussis .
- Whooping cough, or pertussis is a highly-infectious disease which primarily affects children. In addition to causing respiratory complications, whooping cough may result in nerve damage and a high incidence of mortality, particularly in children from low socioeconomic groups and in newborn infants who do not possess maternal anti-pertussis antibodies.
- the etio logic agent of pertussis is the Gram- negative coccobacillus, Bordetella pertussis . The bacteria are believed to invade the respiratory tract and induce a toxic state which remains even after their disappearance, several days later.
- LPF lymphocytosis promoting factor
- PT islet activating protein or, more commonly, pertussis toxin (PT); filamentous hemagglutinin (FHA); fimbrial agglutinogens; and the outer membrane protein of the bacterium, having a molecular weight of approximately 69,000 Daltons, known as pertactin .
- Propagation using submerged aerobic conditions with shaking is suitable for small-scale production, eg. in shake flasks with volumes up to about 5 litres. These conditions are not however representative of large-scale, commercial production where large volume fermenters requiring mechanical agitation are required.
- strains which may be employed include B. pertussis phase I, B. pertussis phase II, B. pertussis phase I CS, B. pertussis Tohama, B. pertussis strain 185-30, B. pertussis strain 18323, B. pertussis strain 134, B. pertussis strain 509, B. pertussis strain Wellcome 28, and Office of Biologies B. pertussis strain 165.
- a preferred strain for use in the present invention is B. pertussis phase I, Tohama, which is available from the Institute of Fermentation, Osaka, Japan under accession number IFO- 14073.
- a suitable medium for growth of a B. pertussis inoculum may be selected by any person skilled in the art.
- suitable media include, without limitation, Gengou medium (EP-A-0 077 646); the media described in N. Andorn et al. (Appl. Microbiol. Biotechnol., 28, 356-360, 1988) and references cited therein; Stainer- Scholte medium (J. Gen. Microbiol. , 63, 211-220, 1971); modified Stainer-Scholte medium described in A. Imaizumi et al (Infect. Immun., 41, 3, 1138-1143, 1983 and J. Microbiol.
- an inoculum is added to a suitable liquid medium and fermentation is conducted as hereinbefore described.
- Persons skilled in the art will appreciate that results may vary depending upon fermenter design, the selected fermentation nutrient medium supplemented with PVA, method and fermentation parameters.
- the preferred nutrient medium for use in the present invention is Stainer-Scholte medium.
- PVA having the requisite MW and degree of hydrolysis is commercially available from a number of manufacmrers.
- Aldrich supplies PVA having a MW range 31,000 to 50,000 and a degree of hydrolysis in the range 87 to 89 mol %
- Sigma supplies PVA having an average MW of 30,000 to 70,000 and a degree of hydrolysis in the range 87 to 89 mol %
- Fluka supplies PVA having a MW of 15,000 and a degree of hydrolysis in the range 86 to 89 mol % and Janssen offers PVA having a specified MW of 22,000 and a specified degree of hydrolysis of 88 mol %.
- Example 1 illustrates the invention, without limitation.
- the surface growth from each Roux bottle was resuspended in modified Stainer- Scholte medium (6 mL) and added to an Erlenmeyer flask (5L) containing modified S.S. medium.
- PVA having a MW and degree of hydrolysis according to the process of the invention was present in the medium in place of ⁇ -2,6-0 dimethyl cyclodextrin, at a final concentration of 2 g/litre.
- the flasks were incubated at 35 °C for 24 hours. The contents of the flasks were pooled to provide the inoculum for 20 L fermenters.
- Inoculum as prepared in Example 2 was added to a fermenter (Biolafitte, Poissy, France) containing 13 litres of filter-sterilised modified Stainer-Scholte medium containing an appropriate PVA, at a final concentration of 2 g/litre.
- the pH was adjusted to and maintained at 7.2 by periodic addition of acetic acid (50 %) and the temperamre was adjusted to and maintained at 35°C.
- Dissolved oxygen was maintained at 20-30 % of saturation by adjustment of the agitation speed and aeration rate.
- a mechanical foambreaker was used to disperse foam generated during the fermentation. Samples of culmre (10-20 ml) were removed periodically from the fermenter throughout the duration of the cultivation (30-40 hours) to determine the mrbidity (optical density at 650 nm) and to follow the growth kinetics.
- the concentrations of both PT and FHA in pre-filtered samples of culture were determined in duplicate by the ELISA technique.
- the test was performed in the presence of two reference samples of PT and FHA of known concentration in order to verify the accuracy of the test.
- the precision of the test was, on average +/- 20 % of the correct value.
- the identity and quality of PT and FHA in pre-filtered samples of culture were determined by Western blot.
- the blot of PT showed the 5 PT sub-unit bands as major components at apparent MW's 29 kDa, 25 kDa, 24 kDa, 14 kDa and 9 kDa.
- the blot of FHA showed the major band at an apparent MW of 220 kDa together with several degradation bands in the region 100 to 200 kDa.
- results obtained using a range of commercially available PVA materials having different MW's and degrees of hydrolysis are given in the following Table. Results from PVA materials falling outside the scope of invention are included for comparison.
- concentrations of PT and FHA are those measured in the final sample from the fermenter in mid-stationary phase, ie. at the end of the cultivation period.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a process for culturing bacteria from the genus Bordetella from which antigens useful in an acellular vaccine may be isolated. The invention results in improved yields of FHA and PT in the culture media and involves culturing the bacteria with specific grades of Polyvinyl alcohol.
Description
NOVEL PROCESS FOR THE PROPAGATION OF B. PERTUSSIS
This invention relates to a process for culturing bacteria belonging to the genus Bordetella for isolation of antigenic proteins useful in the production of whooping cough vaccine. In particular, the invention relates to a process for improving the yield of the major protein components FHA and PT which are secreted into the culture medium during bacterial growth of Bordetella pertussis .
Whooping cough, or pertussis, is a highly-infectious disease which primarily affects children. In addition to causing respiratory complications, whooping cough may result in nerve damage and a high incidence of mortality, particularly in children from low socioeconomic groups and in newborn infants who do not possess maternal anti-pertussis antibodies. The etio logic agent of pertussis is the Gram- negative coccobacillus, Bordetella pertussis . The bacteria are believed to invade the respiratory tract and induce a toxic state which remains even after their disappearance, several days later.
For many years the disease has been controlled through immunisation with "whole cell" vaccine prepared by growing the Bordetella pertussis organism in fermenters and then inactivating the resulting cells by heat treatment and/or addition of chemical agents. Although the World Health Organisation presently recommends the immunisation of infants to prevent the incidence and spread of pertussis, concern has arisen over the reported adverse events resulting from various vaccine formulations. The consequent reduced usage of conventional B. pertussis vaccine has resulted in an increase in the incidence of pertussis infections. In order to avoid the reported adverse events from whole cell vaccine, considerable research effort has been put into the development of an efficaceous acellular vaccine comprising a small number of highly-purified antigenic proteinaceous components.
A number of antigenic proteins have been identified as having utility as vaccine components, including for example lymphocytosis promoting factor (LPF), also known as histamine sensitising factor, islet activating protein or, more commonly, pertussis toxin (PT); filamentous hemagglutinin (FHA); fimbrial agglutinogens; and the outer membrane protein of the bacterium, having a molecular weight of approximately 69,000 Daltons, known as pertactin .
The Bordetella pertussis bacterium is fastidious in its growth requirements. It is unable to utilise carbohydrates, pyruvate, lactate and intermediates of the gylcolysis pathway, relying instead on amino acids, particularly glutamate for its carbon and
energy source in culture media. A suitable glutamate-containing culture medium is described by Stainer and Scholte (J. J. Gen. Microbiol. , 63, 211-220, 1971).
It has been shown that the production of antigenic materials for use in a vaccine against whooping cough involving growth of its etiological agent, Bordetella pertussis, in a suitable liquid culture media can be enhanced by the addition of growth promoting agents to the culture medium.
EP-A-0 077 646 describes a method for enhancing the amount of antigenic materials secreted into the cell-free broth, comprising supplementing the culture medium, suitably Stainer-Scholte medium, with cyclodextrin, in panicular β-2,6-0-dimethyl cyclodextrin.
US 4,551,429 describes the use of an alternative growth promoting agent in B. pertussis propagation under submerged aerobic conditions with shaking of the culture medium. According to US 4,551,429, addition of polyvinyl alcohol (PVA) having a molecular weight (MW) from about 1,500 to 16,000, suitably a 10,000 MW material, at the level of 0.5 to 2.0g/l of medium, also substantially enhances levels of PT and FHA.
Propagation using submerged aerobic conditions with shaking, as described in EP- A-0 077 646 and US 4,551,429, is suitable for small-scale production, eg. in shake flasks with volumes up to about 5 litres. These conditions are not however representative of large-scale, commercial production where large volume fermenters requiring mechanical agitation are required.
A problem arises when the B. pertussis organism is propagated in a large scale fermenter suitable for commercial production of whooping cough vaccine. The problem lies in the tendency for the B. pertussis organism to accumulate at the surface of the liquid culture medium as a foam layer. This results in removal of the bacteria from the growth medium and premature termination of the culture process. A high proportion of the FHA protein secreted by the bacterium also accumulates in this foam layer.
The problem caused by foam production is not solved by addition of growth promoting agents to the culture medium and has moreover been found to be exacerbated when PVA is used in place of cyclodextrin, especially when PVA is present at the upper end of the concentration range disclosed in US 4,551 ,429.
Foam production thus counteracts the beneficial effect of growth promoters, in particular the use of PVA as a growth promoter.
An economic solution to the foaming problem with B. pertussis, using methods commonly used in culture fermentation, is not readily available. Chemical antifoaming agents have not been found to provide a practical solution under normal cultivation conditions. A number of agents have been tested; they were either not tolerated by the B. pertussis bacterium or were found to be effective only for short time periods after which the foam soon returned.
Foambreakers which supress foaming mechanically are commercially available. Because of the susceptibility of the FHA protein to physical degradation if high shear conditions are generated by the foambreaker, particular attention must be given to the design of mechanical foambreakers for large scale B. pertussis culture fermentation.
EP-A-0 121 249 discloses an improved method for production of the protective antigens of B. pertussis on an industrial scale when using a cyclodextrin as a growth promotor in the culture medium. The method requires fermentation to be carried out under defoaming conditions with control of the culture temperature and the amount of dissolved oxygen. The defoaming conditions may be chemical or mechanical, preferably mechanical. EP-A-0 121 249 describes a fermenter producing suitable mechanical defoaming conditions, manufactured by Marubishi Rika KK (Japan). A defoaming vane for a mechanical defoaming apparatus is described in Japanese Patent Publication No. J55-11011 (Marubishi Rika KK).
Large scale propagation of B. pertussis, when carried out according to the method described in EP-A-0 121 249 and using PVA as a growth promotor in the culture medium in place of cyclodextrins, gave variable and disappointing results in terms of reduction in the level of foam production and isolation of acceptable yields of antigenic proteins, especially FHA.
It has now been found that the problem of excessive foam production and the associated decrease in the level of FHA secretion from B. pertussis in large scale fermenters if PVA is used in the culture medium can be overcome by selecting both the MW and the degree of hydrolysis of the PVA added to the culture medium.
Accordingly, the present invention provides a process for commercial scale culture of B. pertussis, comprising propagating the bacterium in an aqueous nutrient medium under submerged aerobic conditions with mechanical agitation and supplementing the nutrient medium with PVA having a molecular weight (MW) in the range 10,000 to 50,000 and a degree of hydrolysis in the range 80 to 90 mol % . Preferably the degree of hydrolysis is 85 to 90 mol % .
According to the invention, commercial scale culture of B. pertussis is suitably carried out in fermenters with a capacity of at least 10 litres, for example in the range 20 to 1000 litres. Foam production is suitably controlled using a mechanical foambreaker which disperses foam generated during fermentation but does not generate high shear conditions in the fermenter, for example a foambreaker of the type described in Japanese Patent Publication No. J55-11011.
Suitable strains of Bordetella pertussis for use in the invention are described in the literature and are readily available in commercial collections such as the American Type Culture Collection, Rockville, Maryland, USA. Any of the available strains may be used in the process of the invention provided it produces at least one, and preferably both of the antigenic proteins PT and FHA in liquid culture medium.
Examples of strains which may be employed include B. pertussis phase I, B. pertussis phase II, B. pertussis phase I CS, B. pertussis Tohama, B. pertussis strain 185-30, B. pertussis strain 18323, B. pertussis strain 134, B. pertussis strain 509, B. pertussis strain Wellcome 28, and Office of Biologies B. pertussis strain 165. A preferred strain for use in the present invention is B. pertussis phase I, Tohama, which is available from the Institute of Fermentation, Osaka, Japan under accession number IFO- 14073.
The selected B. pertussis strain may be grown in a variety of ways known to persons skilled in the art. Cultivation methods are known which employ different cultivation steps, and liquid or solid media, depending on the quantity and origin or conservation methods of the seed culture. However, any known method will suffice for use in the present invention which provides an inoculum of a conventionally- acceptable size for large-scale production.
A suitable medium for growth of a B. pertussis inoculum may be selected by any person skilled in the art. Suitable media include, without limitation, Gengou medium (EP-A-0 077 646); the media described in N. Andorn et al. (Appl.
Microbiol. Biotechnol., 28, 356-360, 1988) and references cited therein; Stainer- Scholte medium (J. Gen. Microbiol. , 63, 211-220, 1971); modified Stainer-Scholte medium described in A. Imaizumi et al (Infect. Immun., 41, 3, 1138-1143, 1983 and J. Microbiol. Methods, 2, 339-347, 1984); Verway medium (US 4,784,589); synthetic medium B2 (P. Van Hemert; Prog. Indust. Microbiol.; (Bull, M. J. ed.), Vol 13, p.151, Elsevier Sci., Amsterdam (1977)) or described modifications thereof.
For growth of B. pertussis culture according to the present invention, an inoculum is added to a suitable liquid medium and fermentation is conducted as hereinbefore described. Persons skilled in the art will appreciate that results may vary depending upon fermenter design, the selected fermentation nutrient medium supplemented with PVA, method and fermentation parameters. The preferred nutrient medium for use in the present invention is Stainer-Scholte medium.
A PVA concentration in the range 0.5 to 2.5 g/1, suitably 1 or 2 g/1 has been found to be most effective in enhancing propagation of PT and FHA.
PVA having the requisite MW and degree of hydrolysis is commercially available from a number of manufacmrers. For example, Aldrich supplies PVA having a MW range 31,000 to 50,000 and a degree of hydrolysis in the range 87 to 89 mol %; Sigma supplies PVA having an average MW of 30,000 to 70,000 and a degree of hydrolysis in the range 87 to 89 mol %; Fluka supplies PVA having a MW of 15,000 and a degree of hydrolysis in the range 86 to 89 mol % and Janssen offers PVA having a specified MW of 22,000 and a specified degree of hydrolysis of 88 mol %.
The PT and FHA may be isolated from the culmre supernatant and purified by known methods. The purified antigen can then be combined optionally with an adjuvant, typically aluminium hydroxide and formulated as a vaccine. The vaccine may advantageously contain pertactin (69kDa omp), which can for example be prepared from the B. pertussis cell grown in accordance with the method of the invention.
The following Examples illustrate the invention, without limitation.
Example 1
Preparation of Master/Working Seeds ) Master Seed
The contents of an ampoule containing Bordetella pertussis Tohama strain (Teijin Ltd., Japan) were reconstituted with deionised water (0.5 mL). The resulting suspension was streaked onto five Petri dishes (0.1 mL/dish) containing B.G. agar (Bordet Gengou, Institut Pasteur, Paris) supplemented with 2% defibrinated sheepblood. After incubation at 35 °C for 24 to 48 hours, the surface growth from each Petri dish was resuspended with 3-5 mL of modified Stainer-Scholte medium (J. Clin. Microbiol., 17(5), 781-786, 1983) supplemented with 10% (v/v) glycerol, and the suspensions were pooled. Aliquots (0.3 mL) of the pooled suspension were placed in plastic cryotubes and immediately frozen and stored at -70°C.
h) Working Seed A plastic cryotube containing Master Seed was thawed to room temperamre and the contents were streaked into each of two glass tubes containing modified S.S. medium supplemented with agar. After incubation at 35 °C for 24 hours, the surface growth from each tube was streaked into two larger glass tubes, each containing modified S.S. medium (35 mL) supplemented with agar. After further incubation at 35 °C for 24 hours, the surface growth from each tube was resuspended with modified S.S. medium (3 mL) and added to an Erlenmeyer flask (IL) containing modified S.S. medium (150 mL). Each flask was placed on an orbital shaker and incubated at 35 °C for 24 hours. The contents of the four flasks were pooled and the suspension was centrifuged at 8000 rpm at 4°C for 15 minutes. The supernatant was discarded and the pellet was resuspended in modified S.S. medium (150 mL) supplemented with 10% (w/v) glycerol. Aliquots (0.4 mL) of the suspension were placed in plastic cryotubes and immediately frozen and stored at -70°C.
F amp.e 2 Preparation of Inoculum Liquid Preculture
Working Seed as prepared in Example 1 (0.08 ml) was incubated at 35°C for 24 hours on solid medium (10 ml) in the form of modified Stainer-Scholte medium supplemented with agar. Surface growth was streaked onto the same medium (35 ml) and incubated at 35°C for 24 hours. Surface growth was suspended with modified Stainer-Scholte medium (3 ml) and added to a Roux bottle (1 litre) containing modified Stainer-Scholte medium (100 ml) supplemented with agar. The Roux bottle was incubated at 35 °C for 24 hours.
The surface growth from each Roux bottle was resuspended in modified Stainer- Scholte medium (6 mL) and added to an Erlenmeyer flask (5L) containing modified S.S. medium. PVA having a MW and degree of hydrolysis according to the process of the invention was present in the medium in place of β-2,6-0 dimethyl cyclodextrin, at a final concentration of 2 g/litre. The flasks were incubated at 35 °C for 24 hours. The contents of the flasks were pooled to provide the inoculum for 20 L fermenters.
Example 3 Growth of Bordetella pertussis in 20 Litre Fermenter
Inoculum as prepared in Example 2 was added to a fermenter (Biolafitte, Poissy, France) containing 13 litres of filter-sterilised modified Stainer-Scholte medium containing an appropriate PVA, at a final concentration of 2 g/litre. The pH was adjusted to and maintained at 7.2 by periodic addition of acetic acid (50 %) and the temperamre was adjusted to and maintained at 35°C. Dissolved oxygen was maintained at 20-30 % of saturation by adjustment of the agitation speed and aeration rate. A mechanical foambreaker was used to disperse foam generated during the fermentation. Samples of culmre (10-20 ml) were removed periodically from the fermenter throughout the duration of the cultivation (30-40 hours) to determine the mrbidity (optical density at 650 nm) and to follow the growth kinetics.
The concentrations of both PT and FHA in pre-filtered samples of culture were determined in duplicate by the ELISA technique. The test was performed in the presence of two reference samples of PT and FHA of known concentration in order to verify the accuracy of the test. The precision of the test was, on average +/- 20 % of the correct value.
The identity and quality of PT and FHA in pre-filtered samples of culture were determined by Western blot. The blot of PT showed the 5 PT sub-unit bands as major components at apparent MW's 29 kDa, 25 kDa, 24 kDa, 14 kDa and 9 kDa. The blot of FHA showed the major band at an apparent MW of 220 kDa together with several degradation bands in the region 100 to 200 kDa.
Example 3
Concentrations of PT and FHA using PVA (2 g/litre^ in a 20 litre Fermenter
The results obtained using a range of commercially available PVA materials having different MW's and degrees of hydrolysis are given in the following Table. Results
from PVA materials falling outside the scope of invention are included for comparison. The concentrations of PT and FHA are those measured in the final sample from the fermenter in mid-stationary phase, ie. at the end of the cultivation period.
Production of PT and FHA with PVA (2 g/L) in 20 L fermenter
MW Degree of Origin Ferm Final Final Average Average range hydrolysi id PT FHA cone final PT final FHA (OOO) s (mol%) BPC cone (mg/L) cone cone
(mg L) (mg/L) (mg L)
9-10 80 Aldrich 435 22 187 22 187
15 86-89 Fluka 269 26 70
425 19 124 22.5 97
13-23 87-88 Aldrich 437 15 179 15 179
13-23 99 Aldrich 436 15 1 1 15 1 1
22 88 Janssen 418 18 106
422 24 182 21 144
22 97.5-99.5 Fluka 415 13 3 416 14 7 13.5 5
22 >98 BDH 438 19 4 19 4
31-50 87-89 Aldrich 419 22 119 421 21 116 21.5 1 17.5
31-50 99 Aldrich 434 22 9 22 9
49 86-89 Fluka 406 8 30 8 30
30-70 87-89 Sigma 264 21 95 384 13 90 17 92.5
50 99 Aldrich 427 10 3 10 3
72 97.5-99.5 Fluka 423 1 1 5 1 1 5
95 85 Janssen 424 14 25 14 25
100 86-89 Fluka 407 8 20 8 20
124-186 99 Aldrich 408 18 3 18 3
Claims
1. A process for commercial scale production of B. pertussis, comprising propagating the bacterium in an aqueous nutrient medium under submerged aerobic conditions with mechanical action and supplementing the media with polyvinyl alcohol (PVA) having a molecular weight in the range of 10,000 to 50,000 and a degree of hydrolysis in the range 80 to 90 mol% .
2. A process as claimed in claim 2, wherein the degree of hydrolysis is in the range 85 to 90%.
3. A process for the production of high yields of B. pertussis Pertussis Toxin (PT) and Filamentous hemagglutinin (FHA), comprising cultivating B. pertussis according to claim 1 and isolating the PT and FHA.
4. A process for the production of a vaccine comprising Pertussis Toxin and Filamentous hemagglutinin capable of affording protection against B. pertussis infections, comprising propagating B. pertussis in an aqueous nutrient medium under submerged conditions with mechanical action and supplementing the media with polyvinyl alcohol having a molecular weight in the range of 10,000 to 50,000 and a degree of hydrolysis in the range 80 to 90 mol%, isolating the Pertussis Toxin and Filamentous hemagglutinin, and formulating as a vaccine, optionally with one or more of pertactin, or fimbrial agglutinogens.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9522839.1A GB9522839D0 (en) | 1995-11-08 | 1995-11-08 | Novel compounds |
GB9522839 | 1995-11-08 | ||
PCT/EP1996/004806 WO1997017427A1 (en) | 1995-11-08 | 1996-11-04 | Novel process for the propagation of b. pertussis |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0953038A1 true EP0953038A1 (en) | 1999-11-03 |
Family
ID=10783548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96938077A Withdrawn EP0953038A1 (en) | 1995-11-08 | 1996-11-04 | Novel process for the propagation of b. pertussis |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0953038A1 (en) |
JP (1) | JP2000500006A (en) |
GB (1) | GB9522839D0 (en) |
WO (1) | WO1997017427A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2430040A1 (en) | 2009-05-11 | 2012-03-21 | Novartis AG | Antigen purification process for pertactin antigen |
CN104152492B (en) * | 2014-07-24 | 2017-03-29 | 农业部环境保护科研监测所 | A kind of method that raising Ka Wuer streptomycete fermentations produce antibiotic yield |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1213234A (en) * | 1983-03-30 | 1986-10-28 | Akihiro Ginnaga | Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine |
US4551429A (en) * | 1983-09-15 | 1985-11-05 | American Home Products Corporation | Stimulation of antigen production by Bordetella pertussis |
FR2596413B1 (en) * | 1986-03-27 | 1988-06-10 | Merieux Inst | NOVEL BACTERIA CULTURE MEDIA BELONGING TO THE GENUS BORDETELLA, CONTAINING ETHERIFIC DERIVATIVES OF D-GLUCOSE POLYMERS, AND THEIR APPLICATION |
DD282471A5 (en) * | 1989-04-21 | 1990-09-12 | Staatliches Inst Fuer Immunpra | METHOD FOR CULTIVATING MICROORGANISMS |
-
1995
- 1995-11-08 GB GBGB9522839.1A patent/GB9522839D0/en active Pending
-
1996
- 1996-11-04 WO PCT/EP1996/004806 patent/WO1997017427A1/en not_active Application Discontinuation
- 1996-11-04 EP EP96938077A patent/EP0953038A1/en not_active Withdrawn
- 1996-11-04 JP JP9517837A patent/JP2000500006A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9717427A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2000500006A (en) | 2000-01-11 |
GB9522839D0 (en) | 1996-01-10 |
WO1997017427A1 (en) | 1997-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4687738A (en) | Method for the production of HA fraction containing protective antigens of Bordetella pertussis and pertussis vaccine | |
US4455297A (en) | Method for producing pertussis toxoid | |
EP0914153A1 (en) | Multivalent dtp-polio vaccines | |
JP2999480B2 (en) | Methods for obtaining protective antigens against pertussis infection and toxic processes | |
US5578308A (en) | Glutaraldehyde and formalin detoxified bordetella toxin vaccine | |
JP6181082B2 (en) | Fermentation method | |
CA2075711C (en) | Vaccine and method therefor | |
JPH08785B2 (en) | Treponema hyodysenteriae bacterin | |
EP0953038A1 (en) | Novel process for the propagation of b. pertussis | |
US6106842A (en) | Extraction of cell-bound protein from bordetella | |
CN109355221B (en) | Culture medium and method for preparing vibrio cholerae ghost through high-density fermentation | |
CN111518717A (en) | Bacillus cereus and inactivated vaccine and application thereof | |
EP0107845A2 (en) | Vaccine for immunizing cattle against infectious bovine keratoconjunctivitis by Moraxella Bovis | |
Barron et al. | Clostridium botulinum type E toxin and toxoid | |
JP2729883B2 (en) | Method for producing organic secretions using cyanobacteria | |
US4758517A (en) | Process for growth of treponema hyodysenteriae | |
US3843451A (en) | Microorganism production | |
CA2081950A1 (en) | Vaccine for the prevention of infections caused by pasteurella haemolytica | |
Reyn et al. | Possible effects of antibiotic treatment on the sensitivity and growth requirements of Neisseria gonorrhoeae | |
JP2022521235A (en) | Fermentation method | |
JPS59181222A (en) | Production of infection protective antigen ha fraction for bordetella pertussis | |
KR101694676B1 (en) | Streptococcus equi strain and the vaccine composition comprising the same | |
RU2270867C2 (en) | METHOD FOR PREPARING Pseudomonas aeruginosa ANATOXIN | |
CA1324075C (en) | Bordetella bronchiseptica vaccine | |
Zadnova et al. | Study on Growth Dynamics of Vibrio cholerae, a Producer of Protective Antigens, under Submerged Culturing and Isolation of Toxin-Coregulated Adhesion Pili |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980427 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE ES FR GB IT LI NL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20000531 |